Cargando…
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people
Age is the strongest determinant of COVID-19 mortality, and over 2 billion people have received primary series vaccination with BNT162b2 (mRNA) or ChAdOx1 (adenoviral vector). However, the profile of sustained vaccine immunogenicity in older people is unknown. Here, we determine spike-specific humor...
Autores principales: | Parry, Helen, Bruton, Rachel, Ayodele, Reni, Sylla, Penny, McIlroy, Graham, Logan, Nicola, Scott, Sam, Nicol, Sam, Verma, Kriti, Stephens, Christine, Willett, Brian, Zuo, Jianmin, Moss, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404227/ https://www.ncbi.nlm.nih.gov/pubmed/36075216 http://dx.doi.org/10.1016/j.xcrm.2022.100739 |
Ejemplares similares
-
COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia
por: Parry, Helen, et al.
Publicado: (2022) -
Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
por: Parry, Helen, et al.
Publicado: (2021) -
Extended interval BNT162b2 vaccination enhances peak antibody generation
por: Parry, Helen, et al.
Publicado: (2022) -
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis
por: Parry, Helen, et al.
Publicado: (2021) -
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
por: Parry, Helen, et al.
Publicado: (2022)